148 results on '"Moretto, Roberto"'
Search Results
102. Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.
- Author
-
Schirripa, Marta, primary, Yang, Dongyun, additional, Loupakis, Fotios, additional, Antoniotti, Carlotta, additional, Cremolini, Chiara, additional, Cao, Shu, additional, Okazaki, Satoshi, additional, Berger, Martin D., additional, Ning, Yan, additional, Miyamoto, Yuji, additional, Suenaga, Mitsukuni, additional, Moretto, Roberto, additional, Bergamo, Francesca, additional, Battaglin, Francesca, additional, Lonardi, Sara, additional, Gopez, Roel, additional, West, Jordan David, additional, Zhang, Wu, additional, Falcone, Alfredo, additional, and Lenz, Heinz-Josef, additional
- Published
- 2016
- Full Text
- View/download PDF
103. Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.
- Author
-
Casagrande, Mariaelena, primary, Moretto, Roberto, additional, Loupakis, Fotios, additional, Cremolini, Chiara, additional, Masi, Gianluca, additional, Borelli, Beatrice, additional, Lonardi, Sara, additional, Marsico, Valentina Angela, additional, Ferrari, Laura, additional, Ricci, Vincenzo, additional, Grande, Roberta, additional, Tomasello, Gianluca, additional, Ronzoni, Monica, additional, Allegrini, Giacomo, additional, Tonini, Giuseppe, additional, Mancini, Maria Laura, additional, Zaniboni, Alberto, additional, Chiara, Silvana, additional, Carlomagno, Chiara, additional, and Falcone, Alfredo, additional
- Published
- 2016
- Full Text
- View/download PDF
104. Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.
- Author
-
Moretto, Roberto, primary, Battaglin, Francesca, additional, Antoniotti, Carlotta, additional, Buggin, Federica, additional, Delliponti, Laura, additional, Bergamo, Francesca, additional, Cremolini, Chiara, additional, Brunello, Antonella, additional, Schirripa, Marta, additional, Menichetti, Alice, additional, Salvatore, Lisa, additional, Marsico, Valentina Angela, additional, Rossini, Daniele, additional, Rumano', Laura, additional, Marmorino, Federica, additional, Falcone, Alfredo, additional, Zagonel, Vittorina, additional, Loupakis, Fotios, additional, and Lonardi, Sara, additional
- Published
- 2016
- Full Text
- View/download PDF
105. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer
- Author
-
Loupakis, Fotios, primary, Moretto, Roberto, additional, Aprile, Giuseppe, additional, Muntoni, Marta, additional, Cremolini, Chiara, additional, Iacono, Donatella, additional, Casagrande, Mariaelena, additional, Ferrari, Laura, additional, Salvatore, Lisa, additional, Schirripa, Marta, additional, Rossini, Daniele, additional, De Maglio, Giovanna, additional, Fasola, Gianpiero, additional, Calvetti, Lorenzo, additional, Pilotto, Sara, additional, Carbognin, Luisa, additional, Fontanini, Gabriella, additional, Tortora, Giampaolo, additional, Falcone, Alfredo, additional, Sperduti, Isabella, additional, and Bria, Emilio, additional
- Published
- 2015
- Full Text
- View/download PDF
106. A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
- Author
-
Pietrantonio, Filippo, primary, Aprile, Giuseppe, additional, Rimassa, Lorenza, additional, Franco, Pierfrancesco, additional, Lonardi, Sara, additional, Cremolini, Chiara, additional, Biondani, Pamela, additional, Sbicego, Elena Lara, additional, Pasqualetti, Francesco, additional, Tomasello, Gianluca, additional, Niger, Monica, additional, Casagrande, Mariaelena, additional, Ghidini, Michele, additional, Muni, Roberta, additional, Montrone, Sabrina, additional, Bergamo, Francesca, additional, Berenato, Rosa, additional, Fontanella, Caterina, additional, Bozzarelli, Silvia, additional, Moretto, Roberto, additional, Battaglin, Francesca, additional, Di Bartolomeo, Maria, additional, de Braud, Filippo, additional, and Miceli, Rosalba, additional
- Published
- 2015
- Full Text
- View/download PDF
107. TAS-102 for the treatment of metastatic colorectal cancer
- Author
-
Salvatore, Lisa, primary, Rossini, Daniele, additional, Moretto, Roberto, additional, Cremolini, Chiara, additional, Schirripa, Marta, additional, Antoniotti, Carlotta, additional, Marmorino, Federica, additional, Loupakis, Fotios, additional, Falcone, Alfredo, additional, and Masi, Gianluca, additional
- Published
- 2015
- Full Text
- View/download PDF
108. Exploring the prognostic and predictive impact of genomic loss of heterozygosity (LOH) in patients with metastatic colorectal cancer (mCRC).
- Author
-
Carullo, Martina, Germani, Marco Maria, Moretto, Roberto, Conca, Veronica, Minelli, Alessandro, Giordano, Mirella, Bruno, Rossella, Prisciandaro, Michele, Lonardi, Sara, Bensi, Maria, Tonini, Giuseppe, Palladino, Maria Angela, Ramundo, Matteo, Tamberi, Stefano, Antoniotti, Carlotta, Rossini, Daniele, Ugolini, Clara, Marmorino, Federica, Fontanini, Gabriella, and Cremolini, Chiara
- Published
- 2023
- Full Text
- View/download PDF
109. Predictive impact of RNF43 mutation (mut) in patients (pts) with pMMR/MSS BRAF V600E mutated metastatic colorectal cancer (mCRC) treated with target therapy (TT) or chemotherapy (CT).
- Author
-
Germani, Marco Maria, Moretto, Roberto, Ros Montañá, Javier, Intini, Rossana, Ghelardi, Filippo, Vetere, Guglielmo, Toledo, Rodrigo De Almeida, Bergamo, Francesca, Randon, Giovanni, Elez, Elena, Lonardi, Sara, Oldani, Simone, Giordano, Mirella, Rossini, Daniele, Ferrari Bravo, Walter, Ricagno, Gianmarco, Vignali, Paola, Ugolini, Clara, Fontanini, Gabriella, and Cremolini, Chiara
- Published
- 2023
- Full Text
- View/download PDF
110. FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
- Author
-
Antoniotti, Carlotta, Rossini, Daniele, Pietrantonio, Filippo, Salvatore, Lisa, Marmorino, Federica, Ambrosini, Margherita, Lonardi, Sara, Bensi, Maria, Moretto, Roberto, Tamberi, Stefano, Toma, Ilaria, Passardi, Alessandro, De Grandis, Maria Caterina, Conca, Veronica, Palermo, Federica, Cappetta, Alessandro, Catteau, Aurelie, Boni, Luca, Galon, Jérôme, and Cremolini, Chiara
- Published
- 2023
- Full Text
- View/download PDF
111. First-line chemotherapy for mCRC—a review and evidence-based algorithm
- Author
-
Cremolini, Chiara, primary, Schirripa, Marta, additional, Antoniotti, Carlotta, additional, Moretto, Roberto, additional, Salvatore, Lisa, additional, Masi, Gianluca, additional, Falcone, Alfredo, additional, and Loupakis, Fotios, additional
- Published
- 2015
- Full Text
- View/download PDF
112. O-014 - Prognostic and predictive role of neutrophils/lymphocytes ratio in metastatic colorectal cancer: A retrospective analysis of the TRIBE study by Gono
- Author
-
Dell' Aquila, Emanuela, Cremolini, Chiara, Zeppola, Tea, Lonardi, Sara, Bergamo, Francesca, Moretto, Roberto, Stellato, Marco, Marmorino, Federica, Battaglin, Francesca, Cortesi, Enrico, Ronzoni, Monica, Tomasello, Gianluca, Zaniboni, Alberto, Racca, Patrizia, Buonadonna, Angela, Allegrini, Giacomo, Fea, Elena, Di Donato, Samantha, Chiara, Silvana, Tonini, Giuseppe, Falcone, Alfredo, and Santini, Daniele
- Published
- 2017
- Full Text
- View/download PDF
113. P-271 - Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study
- Author
-
Moretto, Roberto, Cremolini, Chiara, Morano, Federica, Berenato, Rosa, Tamborini, Elena, Perrone, Federica, Rossini, Daniele, Antoniotti, Carlotta, Marmorino, Federica, Gloghini, Annunziata, Busico, Adele, Zucchelli, Gemma, Baratelli, Chiara, Tamburini, Emiliano, Capone, Iolanda, Volpi, Chiara, Milione, Massimo, Di Maio, Massimo, Fontanini, Gabriella, de Braud, Filippo, Falcone, Alfredo, and Pietrantonio, Filippo
- Published
- 2017
- Full Text
- View/download PDF
114. Risk factors for cancer-related venous thromboembolism in ambulatory patients.
- Author
-
Cella, Chiara Alessandra, primary, Arcopinto, Michele, additional, Lordick, Florian, additional, Carlomagno, Chiara, additional, Matano, Elide, additional, Muehlberg, Katja, additional, Bruzzese, Dario, additional, Moretto, Roberto, additional, Attademo, Laura, additional, Raimondo, Lucia, additional, Schloegl, Haiko, additional, De Stefano, Alfonso, additional, Knoedler, Maren, additional, Stocker, Gertraud, additional, Gabrecht, Maria, additional, and De Placido, Sabino, additional
- Published
- 2014
- Full Text
- View/download PDF
115. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma
- Author
-
Moretto, Roberto, primary, Raimondo, Lucia, additional, De Stefano, Alfonso, additional, Cella, Chiara A., additional, Matano, Elide, additional, De Placido, Sabino, additional, and Carlomagno, Chiara, additional
- Published
- 2013
- Full Text
- View/download PDF
116. Tumor-to-tumor metastasis
- Author
-
Moretto, Roberto, primary, Cella, Chiara A., additional, Raimondo, Lucia, additional, Formisano, Luigi, additional, Nappi, Lucia, additional, Rescigno, Pasquale, additional, Buonerba, Carlo, additional, Calabrese, Filomena, additional, Ottaviano, Margaret, additional, Di Lorenzo, Giuseppe, additional, Matano, Elide, additional, Damiano, Vincenzo, additional, and Palmieri, Giovannella, additional
- Published
- 2013
- Full Text
- View/download PDF
117. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.
- Author
-
Loupakis, Fotios, Moretto, Roberto, Aprile, Giuseppe, Muntoni, Marta, Cremolini, Chiara, Iacono, Donatella, Casagrande, Mariaelena, Ferrari, Laura, Salvatore, Lisa, Schirripa, Marta, Rossini, Daniele, De Maglio, Giovanna, Fasola, Gianpiero, Calvetti, Lorenzo, Pilotto, Sara, Carbognin, Luisa, Fontanini, Gabriella, Tortora, Giampaolo, Falcone, Alfredo, and Sperduti, Isabella
- Subjects
- *
COLON tumors , *METASTASIS , *GENETIC mutation , *ONCOGENES , *TRANSFERASES , *RETROSPECTIVE studies , *STATISTICAL models ,RECTUM tumors - Abstract
Background: In metastatic colorectal cancer (mCRC), BRAFV600E mutation has been variously associated to specific clinico-pathological features.Methods: Two large retrospective series of mCRC patients from two Italian Institutions were used as training-set (TS) and validation-set (VS) for developing a nomogram predictive of BRAFV600E status. The model was internally and externally validated.Results: In the TS, data from 596 mCRC patients were gathered (RAS wild-type (wt) 281 (47.1%); BRAFV600E mutated 54 (9.1%)); RAS and BRAFV600E mutations were mutually exclusive. In the RAS-wt population, right-sided primary (odds ratio (OR): 7.80, 95% confidence interval (CI) 3.05-19.92), female gender (OR: 2.90, 95% CI 1.14-7.37) and mucinous histology (OR: 4.95, 95% CI 1.90-12.90) were independent predictors of BRAFV600E mutation, with high replication at internal validation (100%, 93% and 98%, respectively). A predictive nomogram was calculated: patients with the highest score (right-sided primary, female and mucinous) had a 81% chance to bear a BRAFV600E-mutant tumour; accuracy measures: AUC=0.812, SE:0.034, sensitivity:81.2%; specificity:72.1%. In the VS (508 pts, RAS wt: 262 (51.6%), BRAFV600E mutated: 49 (9.6%)), right-sided primary, female gender and mucinous histology were confirmed as independent predictors of BRAFV600E mutation with high accuracy.Conclusions: Three simple and easy-to-collect characteristics define a useful nomogram for predicting BRAF status in mCRC with high specificity and sensitivity. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
118. Digital Ischemia in Patients with Solid Tumors: a Case Report and Review of the Literature
- Author
-
Raimondo, Lucia, primary, Cella, Chiara Alessandra, additional, Moretto, Roberto, additional, Matano, Elide, additional, and Carlomagno, Chiara, additional
- Published
- 2011
- Full Text
- View/download PDF
119. Coro e Coralidade: (Da Ancestralidade Grega... Do Bumba Meu Boi e da Capoeira... Da Cultura Europeia Contemporânea do Dissenso)
- Author
-
Moretto, Roberto Carlos, primary
- Full Text
- View/download PDF
120. Ensaio.Hamlet: ruptura da linearidade dramática e corpos em rede na cena de Enrique Diaz
- Author
-
Moretto, Roberto Carlos, primary
- Full Text
- View/download PDF
121. Immune Checkpoint Inhibitors in Mismatch Repair Proficient/Microsatellite Stable Metastatic Colorectal Cancer Patients: Insights from the AtezoTRIBE and MAYA Trials.
- Author
-
Germani, Marco Maria and Moretto, Roberto
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *IMMUNE checkpoint inhibitors , *DNA , *GENETIC mutation , *METASTASIS , *IRINOTECAN , *IPILIMUMAB , *COLORECTAL cancer , *TREATMENT effectiveness , *FLUOROURACIL , *TEMOZOLOMIDE , *BEVACIZUMAB , *OXALIPLATIN , *IMMUNOTHERAPY , *DRUG resistance in cancer cells , *THERAPEUTICS - Abstract
Simple Summary: Immune-checkpoint inhibitors (ICI) show modest activity and efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients harbouring a proficient mismatch repair system (pMMR). Recently, two phase 2 trials -AtezoTRIBE and MAYA- have challenged this dogma through the administration of an intense first-line chemotherapy backbone consisting of FOLFOXIRI/bevacizumab in patients unselected for their microsatellite status, and immune priming with temozolomide in chemorefractory pMMR/MSS patients with silencing of O6-methylguanine-DNA methyltransferase (MGMT), respectively, reporting promising results. We here present the founding biological rationale of these two studies and their main findings. At the same time, we stress their strengths and drawbacks and open questions still to be address in future clinical investigations. In metastatic colorectal cancer (mCRC), remarkable advances have been achieved with immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and CTLA-4, only in a small subset of tumours (4–5%), harbouring a deficient mismatch repair system (dMMR)/microsatellite instability–high (MSI-H) or mutations in the catalytic subunit of polymerase epsilon (POLE). Within this framework, several combination strategies have been investigated to sensitize proficient mismatch repair (pMMR)/microsatellite stable (MSS) mCRC to ICIs, with disappointing results so far. However, at the last ESMO meeting, two phase II trials AtezoTRIBE and MAYA provided promising results in this field. In the comparative AtezoTRIBE trial, the addition of atezolizumab to FOLFOXIRI (5-fluoruracil, oxaliplatin and irinotecan) and bevacizumab led to a significant advantage in terms of progression free survival (PFS) in a population of untreated mCRC patients, not selected according to MMR/MSI status. In the single-arm MAYA trial, immune priming with temozolomide in pMMR/MSS chemo-resistant mCRC patients with silencing of O6-methylguanine-DNA methyltransferase (MGMT) allowed reporting signals of sensitivity to the subsequent therapy with nivolumab and a low dose of ipilimumab in some patients. Here, we discuss the rationale, results, criticisms and research perspectives opened by these two studies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
122. Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials.
- Author
-
Rossini, Daniele, Boccaccino, Alessandra, Carullo, Martina, Antoniotti, Carlotta, Dima, Giovanni, Ciracì, Paolo, Marmorino, Federica, Moretto, Roberto, Masi, Gianluca, and Cremolini, Chiara
- Subjects
- *
CONFIDENCE intervals , *SYSTEMATIC reviews , *EPIDERMAL growth factor receptors , *CANCER chemotherapy , *CANCER of unknown primary origin , *RETROSPECTIVE studies , *TREATMENT effectiveness , *COLORECTAL cancer , *CANCER patients , *PROGRESSION-free survival , *ODDS ratio , *BEVACIZUMAB , *OVERALL survival - Abstract
Retrospective subgroup analyses of previous trials in the first-line therapy of RAS wt metastatic colorectal cancer (mCRC) suggested a predictive impact of primary tumour side on the efficacy of anti-epidermal growth factor receptor (EGFR) agents. Recently, new head-to-head trials of doublets/bevacizumab versus doublets/anti-EGFR, PARADIGM and CAIRO5 were presented. We searched for phase II and III trials comparing doublet chemotherapy plus an anti-EGFR or bevacizumab as the first-line treatment for RAS wt mCRC patients. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and radical resection rate result in the overall study populations and, according to the primary side, were pooled together in a two-stage analysis with random effects and fixed effect models. The interaction between sidedness and treatment effect was then analysed. We identified five trials (PEAK, CALGB/SWOG 80405, FIRE-3, PARADIGM and CAIRO5), including 2739 patients, 77% left- and 23% right-sided. Among patients with left-sided mCRC, the use of anti-EGFRs was associated with higher ORR (74% versus 62%, OR = 1.77 [95% confidence interval {CI} 1.39–2.26–0.88], p < 0.0001), longer OS (hazard ratio [HR] = 0.77 [95% CI 0.68–0.88], p < 0.0001) and not significantly longer PFS (HR = 0.92, p = 0.19). Among patients with right-sided mCRC, the use of bevacizumab was associated with longer PFS (HR = 1.36 [95% CI 1.12–1.65], p = 0.002) and not significantly longer OS (HR = 1.17, p = 0.14). A subgroup analysis confirmed a significant interaction effect between the primary tumour side and treatment arm in terms of ORR (p = 0.02), PFS (p = 0.0004) and OS (p = 0.001). No differences in the radical resection rate were found according to treatment and sidedness. Our updated metanalysis corroborates the role of the primary tumour location in the choice of the upfront therapy for RAS wt mCRC patients, leading to strongly recommend anti-EGFRs in left-sided tumours and to prefer bevacizumab in the right-sided. • Doublet/anti-epidermal growth factor receptor (EGFRs) or bevacizumab are both valuable first-line options for RAS wt metastatic colorectal cancer (mCRC). • Left-sided mCRC achieves a better overall survival and overall response rate benefit from anti-EGFRs versus bevacizumab. • Right-sided mCRC patients achieve better progression-free survival , with a trend for overall survivalwith bevacizumab. • Anti-EGFRs should be recommended only in the left-sided RAS wt mCRC. • Bevacizumab should be preferred in the right-sided RAS wt mCRC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
123. Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial.
- Author
-
Antoniotti, Carlotta, Rossini, Daniele, Pietrantonio, Filippo, Catteau, Aurélie, Salvatore, Lisa, Lonardi, Sara, Boquet, Isabelle, Tamberi, Stefano, Marmorino, Federica, Moretto, Roberto, Ambrosini, Margherita, Tamburini, Emiliano, Tortora, Giampaolo, Passardi, Alessandro, Bergamo, Francesca, Kassambara, Alboukadel, Sbarrato, Thomas, Morano, Federica, Ritorto, Giuliana, and Borelli, Beatrice
- Subjects
- *
COLON tumors , *FOLINIC acid , *RESEARCH , *RESEARCH methodology , *ANTINEOPLASTIC agents , *CAMPTOTHECIN , *MONOCLONAL antibodies , *EVALUATION research , *COLORECTAL cancer , *FLUOROURACIL , *ORGANOPLATINUM compounds , *COMPARATIVE studies , *RANDOMIZED controlled trials ,RECTUM tumors - Abstract
Background: Immune checkpoint inhibitors have not shown clinical benefit to patients with metastatic colorectal cancer who had proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumours in previous studies. Both an active combination chemotherapy (FOLFOXIRI; fluorouracil, leucovorin, oxaliplatin, and irinotecan) and bevacizumab seem able to increase the immunogenicity of pMMR or MSS tumours. We aimed to provide preliminary evidence of benefit from the addition of the anti-PD-L1 agent atezolizumab to first-line FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer.Methods: AtezoTRIBE was a multicentre, open-label, randomised, controlled, phase 2 study of patients (aged 18-70 years with an Eastern Cooperative Oncology Group [ECOG] performance status of 0-2 and aged 71-75 years with an ECOG performance status of 0) with histologically confirmed, unresectable, previously untreated metastatic colorectal cancer and adequate organ function, who were recruited from 22 oncology centres in Italy. Patients were stratified according to centre, ECOG performance status, primary tumour site, and previous adjuvant therapy. A randomisation system incorporating a minimisation algorithm randomly assigned (1:2) patients via a masked web-based allocation procedure to two groups: the control group received first-line FOLFOXIRI (intravenous 165 mg/m2 irinotecan, 85 mg/m2 oxaliplatin, 200 mg/m2 leucovorin, and 3200 mg/m2 fluorouracil as a 48 h infusion) plus bevacizumab (5 mg/kg intravenously), and the atezolizumab group received the same regimen plus atezolizumab (840 mg intravenously). Combination treatments were administered up to eight 14-day cycles followed by maintenance with fluorouracil and leucovorin plus bevacizumab with or without atezolizumab, according to randomisation group, until disease progression, unacceptable adverse events, or consent withdrawal. The primary endpoint was progression-free survival, analysed by the intention-to-treat principle. Safety was assessed in patients who received at least one dose of the study treatment. The study recruitment is completed. The trial is registered with Clinicaltrials.gov, NCT03721653.Findings: Between Nov 30, 2018, and Feb 26, 2020, 218 patients were randomly assigned and received treatment (73 in the control group and 145 in the atezolizumab group). At the data cutoff (Aug 1, 2021), median follow-up was 19·9 months (IQR 17·3-23·9). Median progression-free survival was 13·1 months (80% CI 12·5-13·8) in the atezolizumab group and 11·5 months (10·0-12·6) in the control group (hazard ratio [HR] 0·69 [80% CI 0·56-0·85]; p=0·012; adjusted HR 0·70 [80% CI 0·57-0·87]; log-rank test p=0·018). The most frequent all-cause grade 3-4 adverse events were neutropenia (59 [42%] of 142 patients in the atezolizumab group vs 26 [36%] of 72 patients in the control group), diarrhoea (21 [15%] vs nine [13%]), and febrile neutropenia (14 [10%] vs seven [10%]). Serious adverse events were reported in 39 (27%) patients in the atezolizumab group and in 19 (26%) patients in the control group. Two (1%) treatment-related deaths (due to acute myocardial infarction and bronchopulmonary haemorrhage) were reported in the atezolizumab group; none were reported in the control group.Interpretation: The addition of atezolizumab to first-line FOLFOXIRI plus bevacizumab is safe and improved progression-free survival in patients with previously untreated metastatic colorectal cancer.Funding: GONO Foundation, ARCO Foundation, F Hoffmann-La Roche, and Roche. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
124. Upper transversal hepatectomy with double hepatic vein resection and reconstruction to treat colorectal cancer liver metastases at the hepatocaval confluence: a strategy to achieve R0 liver-sparing resection.
- Author
-
Urbani, Lucio, Roffi, Nicolò, Signori, Stefano, Balestri, Riccardo, Colombatto, Piero, Licitra, Gabriella, Leoni, Chiara, Meiattini, Daniele, Moretto, Roberto, Cremolini, Chiara, Masi, Gianluca, Boraschi, Piero, Quilici, Francesca, Buccianti, Piero, and Puccini, Marco
- Subjects
- *
COLORECTAL liver metastasis , *HEPATIC veins , *HEPATECTOMY - Abstract
Background: Repeated hepatectomies in the therapeutic route of patients with colorectal liver metastases (CRLM) may improve their long term survival. Hepatic vein (HV) resection and reconstruction allows parenchyma-sparing hepatectomy (PSH) and R0 resections for CRLM in contact with one HV. We aimed at verifying the feasibility of PSH with double HV resection and direct reconstruction for CRLM in contact with two HVs at the hepatocaval confluence. Methods: Out of 106 consecutive PSH performed for CRLM deep-located in segments I-IVa-VII-VIII, four (3.7%) PSH were performed with resection of CRLM en bloc with two adjacent HVs which were both reconstructed with double direct HV anastomosis: 3 cases between right-HV and middle-HV and 1 case between middle-HV and left-HV. Two patients had previously undergone liver resection. Three patients had one single lesion and one had 5 CRLMs. Results: Median size of CRLMs in contact with HVs was 25 mm (range 22–30 mm). At histological examination, all resections were R0 except one R1-vascular (detachment from glissonean pedicle): in all cases at least one HV and in 1 case both HVs were infiltrated by the tumor cells. After median follow-up of 18 (range 3.5–41.2) months, all HVs were patent. All patients were alive and in good general conditions, and 3 patients were disease free (one of them following a liver re-resection). One patient experienced a grade IIIa complication. Median hospital-stay was 11 (range 9–13) days. Conclusion: In patients with CRLMs involving two adjacent HVs at the hepatocaval confluence, liver resection with double HV resection and direct reconstruction is feasible and may be considered to guarantee oncological radicality (R0) and spare health parenchyma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
125. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
- Author
-
Rossini, Daniele, Lonardi, Sara, Antoniotti, Carlotta, Santini, Daniele, Tomasello, Gianluca, Ermacora, Paola, Germani, Marco Maria, Bergamo, Francesca, Ricci, Vincenzo, Caponnetto, Salvatore, Moretto, Roberto, Zaniboni, Alberto, Pietrantonio, Filippo, Buonadonna, Angela, Ritorto, Giuliana, Masi, Gianluca, Latiano, Tiziana Pia, Rapisardi, Stefania, Falcone, Alfredo, and Cremolini, Chiara
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *DISEASE progression , *FOLINIC acid , *RESEARCH , *RESEARCH methodology , *CANCER relapse , *CAMPTOTHECIN , *MEDICAL cooperation , *EVALUATION research , *COLORECTAL cancer , *ORGANOPLATINUM compounds , *TREATMENT effectiveness , *FLUOROURACIL , *COMPARATIVE studies , *SALVAGE therapy - Abstract
Background: FOLFOXIRI/bevacizumab (bev) is a first-line regimen of proven activity and efficacy in metastatic colorectal cancer. The upfront exposure to three cytotoxics raises concerns about the efficacy of treatments after progression.Methods: We performed a pooled analysis of treatments after progression to upfront FOLFOXIRI/bev in patients enrolled in two randomised Phase 3 studies (TRIBE and TRIBE2) that compared FOLFOXIRI/bev to doublets (FOLFOX or FOLFIRI)/bev. Response rate, progression-free survival (2nd PFS) and overall survival (2nd OS) during treatments after progression were assessed. The RECIST response in first line and the oxaliplatin and irinotecan-free interval (OIFI) were investigated as potential predictors of benefit from FOLFOXIRI ± bev reintroduction.Results: Longer 2nd PFS was reported in patients receiving FOLFOXIRI ± bev reintroduction compared to doublets ± bev or other treatments (6.1 versus 4.4 and 3.9 months, respectively, P = 0.013), and seems limited to patients achieving a response during first line (6.9 versus 4.2 and 4.7 months, respectively, P = 0.005) and an OIFI ≥ 4 months (7.2 versus 6.5 and 4.6 months, respectively, P = 0.045).Conclusions: First-line FOLFOXIRI/bev does not impair the administration of effective second-line therapies. First-line response and longer OIFI seem associated with improved response and 2nd PFS from FOLFOXIRI ± bev reintroduction, without impacting 2nd OS. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
126. The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials.
- Author
-
Fucà, Giovanni, Guarini, Vincenzo, Antoniotti, Carlotta, Morano, Federica, Moretto, Roberto, Corallo, Salvatore, Marmorino, Federica, Lonardi, Sara, Rimassa, Lorenza, Sartore-Bianchi, Andrea, Borelli, Beatrice, Tampellini, Marco, Bustreo, Sara, Claravezza, Matteo, Boccaccino, Alessandra, Murialdo, Roberto, Zaniboni, Alberto, Tomasello, Gianluca, Loupakis, Fotios, and Adamo, Vincenzo
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *RESEARCH , *CLINICAL trials , *RESEARCH methodology , *METASTASIS , *PROGNOSIS , *MEDICAL cooperation , *EVALUATION research , *COLORECTAL cancer , *NEUTROPHILS , *TREATMENT effectiveness , *COMPARATIVE studies , *SURVIVAL analysis (Biometry) , *LEUKOCYTE count , *PLATELET count , *LYMPHOCYTE count - Abstract
Background: Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy.Methods: In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count × monocyte count)/lymphocyte count. A cut-off was determined using the maximally selected rank statistics method. Generalised boosted regression (GBR), the Kaplan-Meier method and Cox hazards regression models were used for survival analyses.Results: A total of 438 patients were included. Overall, 208 patients (47%) had a low-baseline PIV and 230 (53%) had a high-baseline PIV. Patients with high PIV experienced a worse PFS (HR, 1.66; 95% CI, 1.36-2.03, P < 0.001) and worse OS (HR, 2.01; 95% CI, 1.57-2.57; P < 0.001) compared to patients with low PIV. PIV outperformed the other IIBs in the GBR model and in the multivariable models.Conclusion: PIV is a strong predictor of survival outcomes with better performance than other well-known IIBs in patients with mCRC treated with first-line therapy. PIV should be prospectively validated to better stratify mCRC patients undergoing first-line therapy. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
127. Total neoadjuvant treatment and organ preservation strategies in the management of localized rectal cancer: A narrative review and evidence-based algorithm.
- Author
-
Borelli, Beatrice, Germani, Marco Maria, Carullo, Martina, Mattioni, Roberto, Manfredi, Bruno, Sainato, Aldo, Rossi, Piercarlo, Vagli, Paola, Balestri, Riccardo, Buccianti, Piero, Morelli, Luca, Antoniotti, Carlotta, Cremolini, Chiara, Masi, Gianluca, and Moretto, Roberto
- Subjects
- *
RECTAL cancer , *NEOADJUVANT chemotherapy , *PRESERVATION of organs, tissues, etc. , *IMMUNE checkpoint inhibitors , *ADJUVANT chemotherapy , *MEDICAL protocols - Abstract
The multimodal approach with total mesorectal excision preceded by neoadjuvant (chemo)radiotherapy represented the mainstay treatment for locally advanced rectal cancer (LARC) for a long time. However, the benefit of adjuvant chemotherapy in terms of distant relapse reduction is limited. Recently, chemotherapy regimens administered before surgery and incorporated with (chemo)radiotherapy in total neoadjuvant treatment protocols have been established as new options in the management of LARC. Meanwhile, patients with clinical complete response to neoadjuvant treatment can benefit from organ preservation strategies, aimed at sparing surgery and long-term post-operative morbidities, while preserving an adequate disease control. However, the introduction of a non-operative management in clinical practice is a matter of debate with some concerns regarding the risk of local recurrence and long-term outcomes. In this review, we discuss how these recent advances are reshaping the multimodal management of localized rectal cancer and propose an algorithm to place them in the clinical practice. [Display omitted] • Total neoadjuvant treatment is a new option for LARC patients. • NOM is a promising strategy to preserve rectal function in patients with cCR/ncCR. • NOM seems not to compromise oncological outcomes. • dMMR/MSI-H rectal cancer should be treated with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
128. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable
- Author
-
Alessandra Boccaccino, Daniele Rossini, Filippo Pagani, Vincenzo Mazzaferro, Gianluca Masi, Elena Ongaro, Alfredo Falcone, Chiara Cremolini, Lucio Urbani, Beatrice Borelli, Luca Morelli, Roberto Moretto, Francesca Corti, Carlo Sposito, Alessandro Cucchetti, Leonardo Solaini, Beatrice Filippi, Filippo de Braud, Gemma Zucchelli, Filippo Pietrantonio, Ongaro, Elena, Cremolini, Chiara, Rossini, Daniele, Corti, Francesca, Pagani, Filippo, Morelli, Luca, Urbani, Lucio, Masi, Gianluca, Sposito, Carlo, Filippi, Beatrice, Borelli, Beatrice, Zucchelli, Gemma, Moretto, Roberto, Boccaccino, Alessandra, Solaini, Leonardo, de Braud, Filippo, Mazzaferro, Vincenzo, Falcone, Alfredo, Cucchetti, Alessandro, and Pietrantonio, Filippo
- Subjects
Cancer Research ,medicine.medical_specialty ,extrahepatic disease progression ,liver-limited disease ,metastatic colorectal cancer ,Colorectal cancer ,business.industry ,Disease progression ,Disease ,Liver resections ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,lcsh:RC254-282 ,Gastroenterology ,Oncology ,Internal medicine ,Cohort ,medicine ,In patient ,Multivariable model ,business ,Cohort study ,Original Research - Abstract
Background: No tools to predict the probability of extrahepatic disease progression (ePD) of initially unresectable, liver-limited metastatic colorectal cancer (mCRC) are currently available. To estimate the likelihood to develop ePD and to identify clinical and molecular factors that could predict extrahepatic progression-free survival (ePFS), we conducted an observational, retrospective, multicentre cohort study. Methods: We retrospectively identified a cohort of 225 patients with initially unresectable liver-limited disease (LLD), treated from January 2004 to December 2017 with first-line doublets or triplet plus a biological agent at two Italian institutions. Results: 173 (77%) patients experienced ePD which occurred within 1, 2 or 3 years from the diagnosis of mCRC in 15%, 49% and 66% of patients, respectively. Globally, 164 (73%) patients underwent a liver resection at some point of their disease history, and 54 (33%) of them underwent a subsequent locoregional treatment. Age > 70 years, locoregional nodal involvement at diagnosis of colorectal cancer and ≥4 liver metastases were significantly associated with higher risk of ePD while liver resections were associated with reduced risk of ePD. In the multivariable model, number of liver metastases (subdistribution HR, SHR 1.63, 95% CI 1.12 to 2.36; p = 0.01) and liver resections (SHR 0.43, 95% CI 0.29 to 0.63; p = 0.001) were still associated with ePD. Number of liver metastases < 4, no nodal involvement at diagnosis and liver resections were also associated with prolonged ePFS. Conclusions: The identified clinical factors could help physicians in personalising the intensity and aggressiveness of liver-directed treatments in patients with mCRC with initially unresectable LLD.
- Published
- 2019
129. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study
- Author
-
Chiara Alessandra Cella, Dario Bruzzese, Ersilia La Fata, Biagio De Simone, Florian Lordick, Chiara Carlomagno, Roberto Moretto, Katja Sibylle Muehlberg, Michele Arcopinto, Giovanni Di Minno, Sabino De Placido, M. Sodano, Elide Matano, Claudia Arturo, Antonella Tufano, Anna Maria Cerbone, Laura Attademo, Cella, Chiara Alessandra, Di Minno, Giovanni, Carlomagno, Chiara, Arcopinto, Michele, Cerbone, Anna Maria, Matano, Elide, Tufano, Antonella, Lordick, Florian, De Simone, Biagio, Muehlberg, Katja Sibylle, Bruzzese, Dario, Attademo, Laura, Arturo, Claudia, Sodano, Marta, Moretto, Roberto, La Fata, Ersilia, and De Placido, Sabino
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Multivariate analysis ,Population ,030204 cardiovascular system & hematology ,Asymptomatic ,Risk Assessment ,Predictive score ,03 medical and health sciences ,0302 clinical medicine ,Ambulatory care ,Risk Factors ,Internal medicine ,Thromboembolism ,Neoplasms ,Ambulatory Care ,Medicine ,Humans ,education ,Cancer ,Risk stratification ,Aged ,Anticoagulants ,Female ,Lower Extremity ,Middle Aged ,Ultrasonography, Doppler, Duplex ,Venous Thromboembolism ,Ultrasonography ,Univariate analysis ,education.field_of_study ,business.industry ,Risk Factor ,Area under the curve ,Anticoagulant ,Doppler ,Duplex ,Oncology ,Symptom Management and Supportive Care ,030220 oncology & carcinogenesis ,Ambulatory ,Neoplasm ,medicine.symptom ,business ,Risk assessment ,Human - Abstract
Background The efficacy of risk model scores to predict venous thromboembolism (VTE) in ambulatory cancer patients is under investigation, aiming to stratify on an individual risk basis the subset of the cancer population that could mostly benefit from primary thromboprophylaxis. Materials and Methods We prospectively assessed 843 patients with active cancers, collecting clinical and laboratory data. We screened all the patients with a duplex ultrasound (B-mode imaging and Doppler waveform analysis) of the upper and lower limbs to evaluate the right incidence of VTE (both asymptomatic and symptomatic). The efficacy of the existing Khorana risk model in preventing VTE was also explored in our population. Several risk factors associated with VTE were analyzed, leading to the construction of a risk model. The Fine and Gray model was used to account for death as a competing risk in the derivation of the new model. Results The risk factors significantly associated with VTE at univariate analysis and further confirmed in the multivariate analysis, after bootstrap validation, were the presence of metastatic disease, the compression of vascular/lymphatic structures by tumor, a history of previous VTE, and a Khorana score >2. Time-dependent receiving operating characteristic (ROC) curve analysis showed a significant improvement in the area under the curve of the new score over the Khorana model at 3 months (71.9% vs. 57.9%, p = .001), 6 months (75.4% vs. 58.6%, p Conclusion ONKOTEV score steps into history of cancer-related-VTE as a promising tool to drive the decision about primary prophylaxis in cancer outpatients. The validation represents the goal of the prospective ONKOTEV-2 study, endorsed and approved by the European Organization for Research and Treatment of Cancer Young Investigators Program.
- Published
- 2017
130. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma
- Author
-
Lucia Raimondo, Sabino De Placido, Chiara Carlomagno, Chiara Alessandra Cella, Roberto Moretto, Alfonso De Stefano, Elide Matano, Moretto, Roberto, Raimondo, Lucia, DE STEFANO, Alfonso, Cella, CHIARA ALESSANDRA, Matano, E, DE PLACIDO, Sabino, and Carlomagno, Chiara
- Subjects
Male ,Oncology ,Cancer Research ,Leucovorin ,Severity of Illness Index ,Gastroenterology ,Cohort Studies ,Pancreatic tumor ,Antineoplastic Combined Chemotherapy Protocols ,80 and over ,Secondary Prevention ,Pharmacology (medical) ,irinotecan ,Aged, 80 and over ,Middle Aged ,Adult ,Aged ,Biliary Tract Neoplasms ,Camptothecin ,Carcinoma ,Drug Monitoring ,Female ,Fluorouracil ,Gallbladder Neoplasms ,Humans ,Neoplasm Grading ,Neoplasm Staging ,Neutropenia ,Pancreatic Neoplasms ,Survival Analysis ,medicine.anatomical_structure ,FOLFIRI ,medicine.drug ,medicine.medical_specialty ,Pancreatic cancer ,Internal medicine ,medicine ,FOLFIRI Regimen ,Pharmacology ,business.industry ,Gallbladder ,medicine.disease ,Gemcitabine ,Irinotecan ,Regimen ,pancreatic ,biliary tract neoplasm ,business - Abstract
Pancreatic and biliary tract carcinomas are very chemoresistant. After a first-line treatment with a gemcitabine-based regimen, no second-line scheme is consolidated in clinical practice. The aim of this study was to evaluate the toxicity and the activity of the FOLFIRI regimen as first-line or second-line chemotherapy in patients with pancreatic or biliary tract tumors. Fifty-four patients (30 with pancreatic tumor, nine with gallbladder tumor, and 15 with biliary tract tumor) were treated with FOLFIRI (irinotecan 180 mg/m², day 1; leucovorin 100 mg/m² intravenously, days 1 and 2; 5-fluorouracil 400 mg/m² intravenous bolus, days 1 and 2; and 600 mg/m² in 22 h intravenously, continuous infusion days 1 and 2; every 14 days). Toxicity was recorded at each cycle according to the NCI-CTC V3.0 criteria, the response rate was verified each four cycles according to the RECIST criteria, and the progression-free survival rates as well as the overall survival rates were calculated according to the Kaplan-Meier method. Overall, the toxicity was mild. Grade 3-4 neutropenia occurred in 42.6% of patients. Grade 3-4 gastrointestinal toxicity was rare. FOLFIRI as a first-line treatment produced a response rate of 25%. In the second-line group, 9/21 patients (42.9%) obtained a stable disease as best response. In the entire population, the median progression-free survival rates were 3.1 months [95% confidence interval (CI), 1.9-4.4] and 3.5 months (95% CI, 2.6-4.4), respectively, in the first-line and the second-line cohort of patients. The median overall survival rates were 14.5 months (95% CI, 7.0-22.1) and 6.2 months (95% CI, 5.4-7.0), respectively, in the first-line and the second-line cohort of patients. FOLFIRI is feasible and well tolerated in patients with pancreatic or biliary tract tumors; it has a good activity in first line and mostly in patients with pancreatic cancer.
- Published
- 2013
131. Digital Ischemia in Patients with Solid Tumors: a Case Report and Review of the Literature
- Author
-
Roberto Moretto, Elide Matano, Chiara Carlomagno, Lucia Raimondo, Chiara Alessandra Cella, Raimondo, Lucia, Cella, CHIARA ALESSANDRA, Moretto, Roberto, Matano, Elide, and Carlomagno, Chiara
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Colorectal cancer ,Ischemia ,Vasospasm ,paraneoplastic syndrome ,medicine.disease ,Thrombosis ,Oxaliplatin ,Capecitabine ,breast cancer ,Breast cancer ,colon cancer ,medicine ,digital ischemia ,Arteritis ,business ,medicine.drug - Abstract
Digital ischemia is a rare paraneoplastic phenomenon associated with various malignancies, especially adenocarci-nomas. We reported a case of digital ischemia onset during treatment with capecitabine + oxaliplatin, letrozole and epoetin-beta in a 75-year old woman with colon and breast cancer and a secondary hepatic lesion. A literature review disclosed 68 cases of solid neoplasms associated with digital ischemia. The proposed mechanisms of such clinical manifestations are various: vasospasm due to sympathetic hyperactivity, arteritis induced by tumour antigen-antibody complexes deposition or as consequence of immune deregulation, blood hyperviscosity, hypercoagulability or peripheral thrombosis. In the present case, clinical and laboratory evaluations failed to reveal evidence of thrombosis, arteritis, inherited or acquired hypercoagulable state and we postulated the peripheral vasospasm and the sympathetic activity (possibly due to chemotherapy drugs) as potential causes of the digital ischemia.
- Published
- 2011
132. Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion ofetiopathogenesis and diagnostic tools
- Author
-
Giuseppe Ciancia, Chiara Carlomagno, Lucia Raimondo, Francesco Paolo D'Armiento, Idalucia Ferrara, Roberto Moretto, Amalia De Renzo, Chiara Alessandra Cella, Alfonso De Stefano, Raimondo, Lucia, Ferrara, IDA LUCIA, DE STEFANO, Alfonso, Cella, CHIARA ALESSANDRA, D'Armiento, FRANCESCO PAOLO, Ciancia, Giuseppe, Moretto, Roberto, Amalia De, Renzo, and Carlomagno, Chiara
- Subjects
Pathology ,medicine.medical_specialty ,Lymphoma, B-Cell ,Lymphoma ,Colorectal cancer ,Biopsy ,Adenocarcinoma ,Malignancy ,Metastasis ,Female ,Humans ,Liver Neoplasms ,Middle Aged ,Neoplasm Staging ,Neoplasms, Second Primary ,Rectal Neoplasms ,Treatment Outcome ,immune system diseases ,Neoplasms ,hemic and lymphatic diseases ,medicine ,Rectal Adenocarcinoma ,Stage (cooking) ,Rectal cancer ,B cell ,business.industry ,Hepatic non-Hodgkin lymphoma ,B-Cell ,Hematology ,medicine.disease ,Second tumour ,Second Primary ,medicine.anatomical_structure ,Differential diagnosis ,business - Abstract
Primary hepatic lymphoma is an extremely rare malignancy accounting for 0.016% of all cases of non-Hodgkin lymphomas. Approximately 1-4% of histologies described show a follicular pattern. We report a case of primary hepatic non-Hodgkin lymphoma that developed in a middle-aged woman three years after radical treatment (neoadjuvant chemoradiotherapy and surgery) for a rectal adenocarcinoma. Abdomen ultrasound showed a single nodule in the liver, which raised the issue of differential diagnosis with a metastasis from rectal cancer. After surgical removal of the nodule, histology revealed a primary B cell, stage IE follicular non-Hodgkin lymphoma, confined to the liver; indeed, no foci of lymphoma were found elsewhere in the body.
- Published
- 2012
133. Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials.
- Author
-
Moretto R, Vetere G, Carullo M, Ciracì P, Masi G, and Cremolini C
- Abstract
Background: The PRODIGE-23 study showed a higher benefit for FOLFIRINOX (5-fluorouracil, irinotecan and oxaliplatin) as induction chemotherapy followed by long-course chemoradiotherapy (CTRT) respect to neoadjuvant CTRT alone both followed by total mesorectal excision (TME) in terms of disease-free survival (DFS) and overall survival (OS) in locally advanced rectal cancer (LARC). The added value of treatment intensification with irinotecan, over the doublet induction with fluoropyrimidine and oxaliplatin is still debated., Objective: To assess survival, pathological complete response (pCR) rate, and safety from phase II-III trials comparing triplet and doublet induction both followed by CTRT and TME in LARC., Methods: After a systematic literature review of PubMed, Embase, Cochrane, American Society of Clinical Oncology and European Society for Medical Oncology meetings' libraries, data from Kaplan-Meier (KM) curves were extracted from phase II-III clinical trials. Phase II-III trials including at least one treatment arm with doublet or triplet induction chemotherapy without biological agents administered for a minimum of 3 months followed by long-course CTRT and TME and with at least 48 months of follow-up were selected. When available, the neoadjuvant CTRT alone arms of the selected studies were included as a comparator reference treatment. Individual patient DFS and OS data were extracted from Kaplan-Meier plots of original trials through graphical reconstruction between April 10th and May 19th, 2024. A pooled analysis was conducted, and results were validated in a subsequent network meta-analysis (NMA). pCR rates and grade ≥ 3 adverse events rates were also collected. Primary endpoints were DFS and OS between triplet and doublet induction. Secondary endpoints were DFS and OS between neoadjuvant CTRT alone and triplet or doublet induction as well as pCR rates and safety profile among different arms., Results: Out of 674 patients enrolled in 3 trials, 231, 161 and 282 were treated with FOLFIRINOX or CAPOX (capecitabine and oxaliplatin) followed by CTRT or neoadjuvant CTRT alone, respectively. 5-year DFS rates were 73.1 % [95 %CI: 67.2 % - 79.0 %], 61.7 % [95 %CI: 53.9 % - 69.5 %] and 65.1 % [95 %CI: 59.4 % - 70.8 %] for triplet induction, doublet induction, and neoadjuvant CTRT alone, respectively. 5-year OS rates were 86.8 % [95 %CI: 82.3 % - 91.3 %], 74.7 % [95 %CI: 67.6 % - 81.8 %], and 79.6 % [95 %CI: 74.9 % - 84.3 %] for FOLFIRINOX, CAPOX, and neoadjuvant CTRT alone, respectively. Triplet induction showed longer DFS and OS respect to doublet induction (HR for DFS: 0.67 [95 % CI 0.47 - 0.96], p = 0.03; HR for OS: 0.49 [95 % CI 0.31 - 0.78], p = 0.003) with a trend for superiority when compared with neoadjuvant CTRT alone (HR for DFS: 0.77 [95 % CI 0.57 - 1.05], p = 0.10; HR for OS: 0.67 [95 % CI 0.45 - 1.01], p = 0.06). No difference was observed between the doublet induction and neoadjuvant CTRT groups. pCR rates were higher for patients treated with FOLFIRINOX (27.7 %) respect to subjects receiving CAPOX (19.7 %, p = 0.02) or neoadjuvant CTRT alone (12.5 %, p < 0.0001). Triplet was associated with higher rates of severe neutropenia (17 % vs 1 %, p < 0.0001) and nausea-vomiting (11 % vs 3 %, p = 0.02) respect to doublet induction., Conclusions: Induction with FOLFIRINOX showed better survival outcomes and pCR rates respect to CAPOX at the price of increased G3-4 neutropenia and nausea/vomiting. A randomized study comparing triplet and doublet chemotherapy in the frame of a total neoadjuvant treatment strategy is widely warranted., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. C.C. has received honoraria for speaker or advisory roles from Bayer, Roche, Merck Serono, Amgen, Servier, Mirati, Pierre Fabre, MSD, Nordic Pharma and Takeda; and research grants from Bayer, Servier, Merck and Amgen.G.M. has received payment or honoraria for lectures, presentations, speakers bureaux, manuscript writing or educational events from Roche, MSD, Eisai, Terumo, Amgen, Merck Serono; support for attending meetings and or travel from Roche, MSD, Eisai, Terumo, Amgen, Merck Serono; participation on a Data Safety Monitoring Board or Advisory Board from Roche,MSD, Eisai.R.M., G.V., M.C., P.C. declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
134. Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study.
- Author
-
Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, Marmorino F, Moretto R, Prisciandaro M, Tamburini E, Tortora G, Passardi A, Bergamo F, Raimondi A, Ritorto G, Borelli B, Conca V, Ugolini C, Aprile G, Antonuzzo L, Gelsomino F, Martinelli E, Pella N, Masi G, Boni L, Galon J, and Cremolini C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Oxaliplatin administration & dosage, Oxaliplatin therapeutic use, Adult, Organoplatinum Compounds therapeutic use, Organoplatinum Compounds administration & dosage, Camptothecin analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Leucovorin therapeutic use, Leucovorin administration & dosage, Bevacizumab administration & dosage, Bevacizumab therapeutic use, Fluorouracil administration & dosage, Fluorouracil therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Irinotecan therapeutic use, Irinotecan administration & dosage
- Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report 4-year results of the phase II randomized AtezoTRIBE study. Eligible patients with metastatic colorectal cancer (mCRC) received first-line fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI)/bevacizumab (control group, n = 73) or FOLFOXIRI/bevacizumab plus atezolizumab (experimental group, n = 145). We present overall survival (OS) and updated outcomes according to tumor immune-related biomarkers, both in the intention-to-treat (ITT) population and the cohort of patients with proficient mismatch repair (pMMR) tumors. Median follow-up was 45.2 months (IQR, 42.6-49.2). In the ITT population, median OS was 33.0 and 27.2 months for experimental and control groups, respectively (hazard ratio [HR], 0.78 [80% CI, 0.61 to 0.98]; P = .084). An interaction effect between Immunoscore Immune-Checkpoint (IC) and treatment arm was observed ( P
int , .089), with higher benefit from atezolizumab in the Immunoscore IC-high group. In the pMMR cohort (N = 202), median OS was 30.8 and 29.2 months for experimental and control groups, respectively (HR, 0.80 [80% CI, 0.63 to 1.02]; P = .117). Interactions between treatment group and tumor mutational burden (TMB) and Immunoscore IC were reported ( Pint , .043 and .092, respectively), with patients bearing TMB-high and Immunoscore IC-high tumors deriving higher benefit from the addition of atezolizumab. First-line FOLFOXIRI/bevacizumab plus atezolizumab improves OS in patients with mCRC. In the pMMR group, patients with Immunoscore IC-high and/or TMB-high tumors are identified as a subgroup of interest to further develop this treatment.- Published
- 2024
- Full Text
- View/download PDF
135. Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study.
- Author
-
Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, Pietrantonio F, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore-Bianchi A, Stasinos G, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, Weiss MJ, Lønning PE, Poultsides G, Cremolini C, Kreis ME, and D'Angelica M
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Mutation, Propensity Score, Neoplasm Recurrence, Local genetics, Adult, Treatment Outcome, Liver Neoplasms secondary, Liver Neoplasms genetics, Liver Neoplasms surgery, Liver Neoplasms mortality, Hepatectomy methods, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Proto-Oncogene Proteins B-raf genetics
- Abstract
Background: To date, only two studies have compared the outcomes of patients with liver-limited BRAF V600E-mutated colorectal liver metastases (CRLMs) managed with resection versus systemic therapy alone, and these have reported contradictory findings., Methods: In this observational, international, multicentre study, patients with liver-limited BRAF V600E-mutated CRLMs treated with resection or systemic therapy alone were identified from institutional databases. Patterns of recurrence/progression and overall survival were compared using multivariable analyses of the entire cohort and a propensity score-matched cohort., Results: Of 170 patients included, 119 underwent hepatectomy and 51 received systemic treatment. Surgically treated patients had a more favourable pattern of recurrence with most recurrences limited to a single site, whereas diffuse progression was more common among patients who received systemic treatment (19 versus 44%; P = 0.002). Surgically treated patients had longer median overall survival (35 versus 20 months; P < 0.001). Hepatectomy was independently associated with better OS than systemic treatment alone (HR 0.37, 95% c.i. 0.21 to 0.65). In the propensity score-matched cohort, surgically treated patients had longer median overall survival (28 versus 20 months; P < 0.001); hepatectomy was independently associated with better overall survival (HR 0.47, 0.25 to 0.88)., Conclusion: BRAF V600E mutation should not be considered a contraindication to surgery for patients with resectable, liver-only CRLMs., (© The Author(s) 2024. Published by Oxford University Press on behalf of BJS Foundation Ltd. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
136. Vessel-Guided Mesohepatectomy for Liver Partition and Staged Major Parenchyma-Sparing Hepatectomies with Super-Selective Portal Vein Embolization or Enhanced ALPPS to Achieve R0 Resection for Colorectal Liver Metastases at the Hepatocaval Confluence.
- Author
-
Urbani L, Roffi N, Moretto R, Signori S, Balestri R, Rossi E, Colombatto P, Licitra G, Leoni C, Martinelli R, Meiattini DA, Bonistalli E, Borelli B, Antoniotti C, Masi G, Rossini D, Boraschi P, Donati F, Della Pina MC, Lunardi A, Daviddi F, Crocetti L, Tonerini M, Gigoni R, Quilici F, Gaeta R, Turco F, Paolicchi A, Volterrani D, Nardini V, Buccianti P, Forfori F, Puccini M, and Cremolini C
- Abstract
Background . R0 minor parenchyma-sparing hepatectomy (PSH) is feasible for colorectal liver metastases (CRLM) in contact with hepatic veins (HV) at hepatocaval confluence since HV can be reconstructed, but in the case of contact with the first-order glissonean pedicle (GP), major hepatectomy is mandatory. To pursue an R0 parenchyma-sparing policy, we proposed vessel-guided mesohepatectomy for liver partition (MLP) and eventually combination with liver augmentation techniques for staged major PSH. Methods . We analyzed 15 consecutive vessel-guided MLPs for CRLM at the hepatocaval confluence. Patients had a median of 11 (range: 0-67) lesions with a median diameter of 3.5 cm (range: 0.0-8.0), bilateral in 73% of cases. Results . Grade IIIb or more complications occurred in 13%, median hospital stay was 14 (range: 6-62) days, 90-day mortality was 0%. After a median follow-up of 17.5 months, 1-year OS and RFS were 92% and 62%. In nine (64%) patients, MLP was combined with portal vein embolization (PVE) or ALPPS to perform staged R0 major PSH. Future liver remnant (FLR) volume increased from a median of 15% (range: 7-20%) up to 41% (range: 37-69%). Super-selective PVE was performed in three (33%) patients and enhanced ALPPS (e-ALPPS) in six (66%). In two e-ALPPS an intermediate stage of deportalized liver PSH was necessary to achieve adequate FLR volume. Conclusions . Vessel-guided MLP may transform the liver in a paired organ. In selected cases of multiple bilobar CRLM, to guarantee oncological radicality (R0), major PSH is feasible combining advanced surgical parenchyma sparing with liver augmentation techniques when FLR volume is insufficient.
- Published
- 2023
- Full Text
- View/download PDF
137. Demystifying BRAF Mutation Status in Colorectal Liver Metastases : A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions.
- Author
-
Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore-Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, Pietrantonio F, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultsides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, Weiss MJ, Cremolini C, Benoist S, and D'Angelica M
- Subjects
- Humans, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras) genetics, Prognosis, Hepatectomy methods, Mutation, Colorectal Neoplasms pathology, Liver Neoplasms genetics, Liver Neoplasms surgery, Liver Neoplasms secondary
- Abstract
Objective: To investigate the clinical implications of BRAF -mutated (mut BRAF ) colorectal liver metastases (CRLMs)., Background: The clinical implications of mut BRAF status in CRLMs are largely unknown., Methods: Patients undergoing resection for mut BRAF CRLM were identified from prospectively maintained registries of the collaborating institutions. Overall survival (OS) and recurrence-free survival (RFS) were compared among patients with V600E versus non-V600E mutations, KRAS/BRAF comutation versus mut BRAF alone, microsatellite stability status (Microsatellite Stable (MSS) vs instable (MSI-high)), upfront resectable versus converted tumors, extrahepatic versus liver-limited disease, and intrahepatic recurrence treated with repeat hepatectomy versus nonoperative management., Results: A total of 240 patients harboring BRAF -mutated tumors were included. BRAF V600E mutation was associated with shorter OS (30.6 vs 144 mo, P =0.004), but not RFS compared with non-V600E mutations. KRAS/BRAF comutation did not affect outcomes. MSS tumors were associated with shorter RFS (9.1 vs 26 mo, P <0.001) but not OS (33.5 vs 41 mo, P =0.3) compared with MSI-high tumors, whereas patients with resected converted disease had slightly worse RFS (8 vs 11 mo, P =0.01) and similar OS (30 vs 40 mo, P =0.4) compared with those with upfront resectable disease. Patients with extrahepatic disease had worse OS compared with those with liver-limited disease (8.8 vs 40 mo, P <0.001). Repeat hepatectomy after intrahepatic recurrence was associated with improved OS compared with nonoperative management (41 vs 18.7 mo, P =0.004). All results continued to hold true in the multivariable OS analysis., Conclusions: Although surgery may be futile in patients with BRAF -mutated CRLM and concurrent extrahepatic disease, resection of converted disease resulted in encouraging survival in the absence of extrahepatic spread. Importantly, second hepatectomy in select patients with recurrence was associated with improved outcomes. Finally, MSI-high status identifies a better prognostic group, with regard to RFS while patients with non-V600E mutations have excellent prognosis., Competing Interests: The authors report no conflicts of interest., (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
138. ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
- Author
-
Borelli B, Conca V, Carullo M, Sainato A, Mattioni R, Manfredi B, Balestri R, Buccianti P, Morelli L, Rossi P, Vagli P, Prete AA, Luca F, Morano F, Donato SD, Salvatore L, Bengala C, Rossini D, Boni L, Antoniotti C, Cremolini C, Masi G, and Moretto R
- Subjects
- Humans, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemoradiotherapy methods, Consolidation Chemotherapy methods, Neoadjuvant Therapy methods, Prospective Studies, Neutropenia, Rectal Neoplasms drug therapy, Rectal Neoplasms pathology
- Abstract
Background: In patients with locally advanced rectal cancer (LARC) treated with preoperative (chemo) radiotherapy and surgery, adjuvant chemotherapy is poorly feasible and its benefit is questionable. In the last years, several total neoadjuvant treatment (TNT) strategies, moving the adjuvant chemotherapy to the neoadjuvant setting, have been investigated with the aim of improving compliance to systemic chemotherapy, treating micrometastases earlier and then reducing distant recurrence., Patients and Methods: ShorTrip (NTC05253846) is a prospective, multicentre, single-arm phase II trial where 63 patients with LARC will be treated with short-course radiotherapy followed by intensified consolidation chemotherapy with FOLFOXIRI regimen and surgery. Primary endpoint is pCR. Among the first 11 patients who started consolidation chemotherapy, a preliminary safety analysis showed a high rate of grade 3 to 4 neutropenia (N = 7, 64%) during the first cycle of FOLFOXIRI. Therefore, the protocol has been emended with the recommendation to omit irinotecan during the first cycle of consolidation chemotherapy. After amendment, in a subsequent safety analysis focused on the first 9 patients treated with FOLFOX as first cycle and then with FOLFOXIRI, grade 3 to 4 neutropenia was reported in only one case during the second cycle., Aim of the Study: The aim of this study is to assess the safety and activity of a TNT strategy including SCRT, intensified consolidation treatment with FOLFOXIRI and delayed surgery. After protocol amendment, the treatment seems feasible without safety concern. Results are expected at the end of 2024., Competing Interests: Disclosure The authors have stated that they have no conflicts of interest., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
139. Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
- Author
-
Moretto R, Germani MM, Giordano M, Conca V, Proietti A, Niccoli C, Pietrantonio F, Lonardi S, Tamburini E, Zaniboni A, Passardi A, Latiano TP, Fanotto V, Di Donato S, Prisciandaro M, Bergamo F, Masi G, Fontanini G, Ugolini C, and Cremolini C
- Subjects
- Humans, Bevacizumab therapeutic use, Prognosis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Camptothecin, Fluorouracil, Leucovorin, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Colonic Neoplasms drug therapy, Rectal Neoplasms drug therapy
- Abstract
Background: Trop-2 and Nectin-4 are transmembrane proteins overexpressed in many tumours and targets of antibody-drug conjugates (ADC). In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated., Methods: Tumour samples of patients randomised in the phase III TRIBE2 were assessed for Trop-2 and Nectin-4 expression., Results: Three hundred eighty-six tumours were assessed for Trop-2 expression. 90 (23%), 115 (30%) and 181 (47%) were Trop-2 high, medium and low, respectively. Patients with low Trop-2 tumours achieved longer PFS (12 versus 9.9 months, p = 0.047) and OS (27.3 versus 21.3 months, p = 0.015) than those with high/medium Trop-2 tumours. These findings were confirmed in multivariate analysis (p = 0.022 and p = 0.023, respectively). A greater OS benefit from treatment intensification with FOLFOXIRI/bevacizumab was observed in patients with high/medium Trop-2 tumours (p-for-interaction = 0.041). Two hundred fifty-one tumours were assessed for Nectin-4 expression. Fourteen (5%), 67 (27%) and 170 (68%) were high, medium and low, respectively. No prognostic impact was observed based on Nectin-4 expression and no interaction effect was reported between Nectin-4 expression groups and treatment arm., Conclusions: In mCRC, expression levels of Trop-2 and Nectin-4 are heterogeneous, suggesting a target-driven development of anti-Trop2 and anti-Nectin-4 ADCs. Medium/high Trop-2 expression is associated with worse prognosis and higher benefit from chemotherapy intensification., (© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
140. Impact of baseline gadoxetic acid-enhanced liver magnetic resonance and diffusion-weighted imaging in resectable colorectal liver metastases: A prospective, monocentric study.
- Author
-
Moretto R, Borelli B, Boraschi P, Roffi N, Donati F, Antoniotti C, Della Pina C, Colombatto P, Balestri R, Signori S, Gigoni R, Guidoccio F, Volterrani D, Masi G, Cremolini C, and Urbani L
- Subjects
- Biological Factors therapeutic use, Contrast Media pharmacology, Contrast Media therapeutic use, Gadolinium DTPA, Humans, Magnetic Resonance Imaging methods, Magnetic Resonance Spectroscopy, Oxaliplatin therapeutic use, Prospective Studies, Colorectal Neoplasms pathology, Liver Neoplasms diagnostic imaging, Liver Neoplasms drug therapy, Liver Neoplasms surgery
- Abstract
Background: Liver magnetic resonance imaging (MRI) utilizing hepatocyte-specific contrast agent and diffusion-weighted imaging (DWI) is currently used to properly stage colorectal liver metastases (CRLM) in patients candidate to liver surgery. However, the added value of liver MRI in choosing the treatment strategy in resectable CRLM over computed tomography (CT)-scan is not clear., Patients and Methods: This is a prospective monocentric collection of consecutive cases of patients with CRLM conceived with the aim to assess the added value of liver MRI in changing the initial treatment strategy planned according to CT-scan. Potential changes in the initially planned strategy were defined as: - from upfront surgery to perioperative chemotherapy (fluoropyrimidine and oxaliplatin) - from upfront surgery to first-line systemic therapy (doublet or triplet plus a biological agent) - from perioperative chemotherapy to first-line systemic therapy. Hypothesising that MRI may induce a change in the choice of the treatment strategy in the 20% of cases (alternative hypothesis), against a null hypothesis of 5%, with one-tailed alpha and beta errors of 0.05 and 0.20 respectively, 27 patients were needed. The added value of liver MRI would have been considered clinically meaningful if at least 4 changes in the treatment strategy were observed., Results: Among 27 enrolled patients, upfront surgery and perioperative chemotherapy strategies were chosen in 17 (63%) and 10 (37%) cases, respectively, based on CT-scan. After liver MRI, additional liver lesions were found in 8 patients (30%) and the initial strategy was changed in 7 patients (26%) (4 initially deemed candidate to upfront surgery and 3 initially sent to perioperative chemotherapy) that were treated with first-line systemic therapy., Conclusions: Our results support the indication of the current guidelines on the routine use of liver MRI in the initial workup of patients with resectable CRLM with an MRI-driven changes of initial treatment plan in a relevant percentage of cases., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
141. Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
- Author
-
Moretto R, Elliott A, Rossini D, Intini R, Conca V, Pietrantonio F, Sartore-Bianchi A, Antoniotti C, Rasola C, Scartozzi M, Salati M, Pella N, Calegari MA, Carullo M, Corti F, Mauri G, Fassan M, Masi G, Brodskiy P, Lenz HJ, Shields A, Lonardi S, Korn M, and Cremolini C
- Subjects
- Camptothecin analogs & derivatives, Colonic Neoplasms drug therapy, Colonic Neoplasms genetics, Colonic Neoplasms secondary, Fluorouracil adverse effects, Humans, Leucovorin adverse effects, Organoplatinum Compounds, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Bevacizumab therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Colorectal Neoplasms secondary, Rectal Neoplasms chemically induced
- Abstract
Background: Recent data suggest that BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients with right-sided tumours and ECOG-PS = 0 may achieve benefit from the triplet regimen differently than those with left-sided tumours and ECOG-PS > 0., Methods: The predictive impact of primary sidedness and ECOG-PS was evaluated in a large real-life dataset of 296 BRAFV600E-mutated mCRC patients treated with upfront triplet or doublet ± bevacizumab. Biological differences between right- and left-sided BRAFV600E-mutated CRCs were further investigated in an independent cohort of 1162 samples., Results: A significant interaction effect between primary sidedness and treatment intensity was reported in terms of both PFS (p = 0.010) and OS (p = 0.003), with a beneficial effect of the triplet in the right-sided group and a possible detrimental effect in the left-sided. No interaction effect was observed between ECOG-PS and chemo-backbone. In the MSS/pMMR population, a consistent trend for a side-related subgroup effect was observed when FOLFOXIRI ± bevacizumab was compared to oxaliplatin-based doublets±bevacizumab (p = 0.097 and 0.16 for PFS and OS, respectively). Among MSS/pMMR tumours, the BM1 subtype was more prevalent in the right-sided group (p = 0.0019, q = 0.0139). No significant differences were observed according to sidedness in the MSI-H/dMMR population., Conclusions: Real-life data support the use of FOLFOXIRI ± bevacizumab only in BRAFV600E-mutated mCRC patients with right-sided tumours., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2022
- Full Text
- View/download PDF
142. Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients.
- Author
-
Moretto R, Rossini D, Capone I, Boccaccino A, Perrone F, Tamborini E, Masi G, Antoniotti C, Marmorino F, Conca V, Borelli B, Martignetti A, Pecora I, Simionato F, Cupini S, Ambrosini M, Manca P, Pietrantonio F, Falcone A, and Cremolini C
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Panitumumab therapeutic use, Phenylurea Compounds, Prospective Studies, Pyridines, Retrospective Studies, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Proto-Oncogene Proteins B-raf genetics
- Abstract
Background: A recent phase II randomized Japanese study reported better survival with regorafenib followed at progression by cetuximab ± irinotecan compared with the reverse standard sequence in chemo-refractory and anti-EGFR-naïve, RAS wild-type (wt) mCRC patients. Nowadays the use of anti-EGFR antibodies is more frequently anticipated to the first-line of therapy especially in patients with left-sided RAS/BRAF wt tumours. However, retrospective analyses and phase II single-arm trials showed promising activity of re-using anti-EGFRs in metastatic colorectal cancer (mCRC) patients who previously achieved benefit from a first-line anti-EGFR-based treatment. Post-hoc analyses of these trials revealed that the detection of RAS mutations in circulating tumour DNA (ct-DNA) at the time of re-treatment may be useful to identify resistant patients., Patients and Methods: PARERE (NCT04787341) is a prospective, open label, multicentre phase II study in which 214 RAS/BRAF wt chemo-refractory mCRC patients with previous benefit from first-line anti-EGFR-based treatment and RAS/BRAF wt ct-DNA in the liquid biopsy collected at the time of inclusion will be randomized in a 1:1 ratio to receive panitumumab followed after progression by regorafenib versus the reverse sequence. Primary endpoint is overall survival. Secondary endpoints are 1st-progression free-survival (PFS), 2nd-PFS, time to failure strategy, objective response rate, and safety., Aim of the Study: The aim of this study is to validate the role of anti-EGFR retreatment and its proper placement in the therapeutic route of mCRC patients selected according to the analysis of ct-DNA in liquid biopsy. Results are expected at the end of 2023., (Copyright © 2021. Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF
143. CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies.
- Author
-
Moretto R, Rossini D, Conca V, Lonardi S, Rasola C, Antoniotti C, Santini D, Marmorino F, Tomasello G, Borelli B, Caponnetto S, Zucchelli G, Zaniboni A, Ambrosini M, Buonadonna A, Fanchini L, Cupini S, Masi G, Falcone A, and Cremolini C
- Subjects
- Adult, Aged, Clinical Trials, Phase III as Topic, Colorectal Neoplasms metabolism, Disease Progression, Female, Humans, Male, Middle Aged, Multicenter Studies as Topic, Neoplasm Metastasis, Prognosis, Randomized Controlled Trials as Topic, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor metabolism, Carcinoembryonic Antigen metabolism, Colorectal Neoplasms drug therapy, Induction Chemotherapy methods
- Abstract
Background: In mCRC, CEA is used to monitor response to systemic therapy together with imaging. After the end of induction, no major improvement in tumour shrinkage is expected, and the availability of a marker able to predict progressive disease (PD) versus no-PD might allow avoiding CT scans., Methods: We pooled data from patients with baseline CEA ≥ 10 ng/mL included in TRIBE and TRIBE2 studies with the aim of identifying a threshold for percent increase of CEA from nadir able to predict PD after the end of the induction therapy., Results: In total, 1178 paired CEA and radiological assessments from 434 patients were included. According to the optimal cut-off determined by ROC, a CEA increase of at least 120% from nadir differentiated between PD and no-PD with a sensitivity of 74% and a specificity of 78%, excluding PD in the 92% of radiological assessments and allowing to avoid the 67% of CT scans. However, CEA cut-off of 120% was not able to detect radiological PD in 26% of cases. In order to mitigate this issue, a different clinically relevant threshold was evaluated based on the best sensitivity cut-off. Therefore, using any CEA increase from nadir as a threshold, the sensitivity grew to 93% and only in the 7% of cases the radiological PD was not detected., Conclusions: In mCRC with baseline CEA ≥ 10 ng/mL, CEA values can accurately predict PD versus no-PD after the end of the first-line induction therapy., (© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
- Published
- 2021
- Full Text
- View/download PDF
144. Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.
- Author
-
Orlandi P, Gentile D, Banchi M, Cucchiara F, Di Desidero T, Cremolini C, Moretto R, Falcone A, and Bocci G
- Subjects
- Apoptosis, Colonic Neoplasms pathology, Drug Combinations, Fluorouracil administration & dosage, Humans, Pyrrolidines administration & dosage, Thymine administration & dosage, Trifluridine administration & dosage, Tumor Cells, Cultured, Antineoplastic Combined Chemotherapy Protocols pharmacology, Cell Proliferation, Colonic Neoplasms drug therapy, Drug Synergism
- Abstract
The aim of this study was to investigate possible synergistic effects in vitro of trifluridine/tipiracil (TAS-102) and 5-fluoruracil (5-FU) on fluoropyrimidine-sensitive colon cancer cell lines of different mutational status in order to build a rational basis for the future use of this combination therapy in adjuvant settings or as a first-line treatment for metastatic disease. Proliferation assays were performed on HT-29 (B-raf mutated), SW-620 (ras mutated), and Caco-2 (wild type) colon cancer cell lines exposed to 120-h treatments of 5-FU, TAS-102 and their different combination schedules (simultaneous, sequential and reverse) at equimolar and non-equimolar ratios. The synergistic, additive and antagonistic effects of 5-FU and TAS-102 were determined by the combination index (CI) and dose reduction index (DRI). Our preclinical in vitro results may suggest an apparently counterintuitive but strongly synergistic combination of 5-FU and TAS-102 in fluoropyrimidine-sensitive colon cancer cells allowing a marked theoretical reduction in the administered doses of both drugs. In particular, this association seems to be highly effective in wild-type colon cancer cells, both in sequential and simultaneous schedules. Together, these data may build a rational basis for the future use of TAS-102 combined with 5-FU in adjuvant settings, or as a first-line treatment for metastatic disease.
- Published
- 2020
- Full Text
- View/download PDF
145. A validated prognostic classifier for V600E BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study.
- Author
-
Loupakis F, Intini R, Cremolini C, Orlandi A, Sartore-Bianchi A, Pietrantonio F, Pella N, Spallanzani A, Dell'Aquila E, Scartozzi M, De Luca E, Rimassa L, Formica V, Leone F, Calvetti L, Aprile G, Antonuzzo L, Urbano F, Prenen H, Negri F, Di Donato S, Buonandi P, Tomasello G, Avallone A, Zustovich F, Moretto R, Antoniotti C, Salvatore L, Calegari MA, Siena S, Morano F, Ongaro E, Cascinu S, Santini D, Ziranu P, Schirripa M, Buggin F, Prete AA, Depetris I, Biason P, Lonardi S, Zagonel V, Fassan M, and Di Maio M
- Subjects
- Adult, Aged, Aged, 80 and over, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Colorectal Neoplasms therapy, Female, Genetic Predisposition to Disease, Humans, Italy, Male, Middle Aged, Neoplasm Metastasis, Phenotype, Predictive Value of Tests, Prognosis, Retrospective Studies, Risk Assessment, Risk Factors, Young Adult, Biomarkers, Tumor genetics, Colorectal Neoplasms genetics, DNA Mutational Analysis, Mutation, Proto-Oncogene Proteins B-raf genetics
- Abstract
Background: Despite the well-known negative prognostic value of the
V600E BRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined., Methods: Two large retrospective series ofV600E BRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated., Results: A total of 395V600E BRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a 'complete' score (0-16) including all significant covariates and a 'simplified' score (0-9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0-4), intermediate (5-8) and high (9-16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44-3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72-8.20, p < .001). Similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. The simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation., Conclusions: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses., (Copyright © 2019 Elsevier Ltd. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
146. Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.
- Author
-
Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, and Pietrantonio F
- Abstract
Background: No tools to predict the probability of extrahepatic disease progression (ePD) of initially unresectable, liver-limited metastatic colorectal cancer (mCRC) are currently available. To estimate the likelihood to develop ePD and to identify clinical and molecular factors that could predict extrahepatic progression-free survival (ePFS), we conducted an observational, retrospective, multicentre cohort study., Methods: We retrospectively identified a cohort of 225 patients with initially unresectable liver-limited disease (LLD), treated from January 2004 to December 2017 with first-line doublets or triplet plus a biological agent at two Italian institutions., Results: 173 (77%) patients experienced ePD which occurred within 1, 2 or 3 years from the diagnosis of mCRC in 15%, 49% and 66% of patients, respectively. Globally, 164 (73%) patients underwent a liver resection at some point of their disease history, and 54 (33%) of them underwent a subsequent locoregional treatment. Age > 70 years, locoregional nodal involvement at diagnosis of colorectal cancer and ≥4 liver metastases were significantly associated with higher risk of ePD while liver resections were associated with reduced risk of ePD. In the multivariable model, number of liver metastases (subdistribution HR, SHR 1.63, 95% CI 1.12 to 2.36; p = 0.01) and liver resections (SHR 0.43, 95% CI 0.29 to 0.63; p = 0.001) were still associated with ePD. Number of liver metastases < 4, no nodal involvement at diagnosis and liver resections were also associated with prolonged ePFS., Conclusions: The identified clinical factors could help physicians in personalising the intensity and aggressiveness of liver-directed treatments in patients with mCRC with initially unresectable LLD., Competing Interests: Competing interests: None declared.
- Published
- 2019
- Full Text
- View/download PDF
147. TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer.
- Author
-
Borelli B, Moretto R, Lonardi S, Bonetti A, Antoniotti C, Pietrantonio F, Masi G, Burgio V, Marmorino F, Salvatore L, Rossini D, Zaniboni A, Zucchelli G, Martignetti A, Di Battista M, Pella N, Passardi A, Boccaccino A, Leone F, Colombo C, Granetto C, Vannini F, Marsico VA, Martinelli E, Antonuzzo L, Vitello S, Delliponti L, Boni L, Cremolini C, and Falcone A
- Abstract
Background: FOLFOXIRI plus bevacizumab is considered a standard option in the upfront treatment of clinically selected patients with metastatic colorectal cancer irrespective of RAS and BRAF molecular status. The randomised MACBETH and VOLFI studies showed that a modified FOLFOXIRI regimen in combination with cetuximab or panitumumab, respectively, achieved high therapeutic activity in RAS and BRAF wild-type patients with an acceptable toxicity profile. Drawing from these considerations, we designed TRIPLETE study aiming at comparing two different chemotherapy backbones (mFOLFOXIRI or mFOLFOX6) in combination with panitumumab in the first-line treatment of patients with RAS and BRAF wild-type metastatic colorectal cancer., Methods: This is a prospective, open-label, multicentre phase III trial in which initially unresectable and previously untreated RAS and BRAF wild-type metastatic colorectal cancer patients are randomised to receive a standard treatment with mFOLFOX6 plus panitumumab or an experimental regimen with modified FOLFOXIRI (irinotecan 150 mg/m
2 , oxaliplatin 85 mg/m2 , L-leucovorin 200 mg/m2 , 5-fluoruracil 2400 mg/m2 48-hour continuous infusion) plus panitumumab up to 12 cycles, followed by panitumumab plus 5-fluorouracil and L-leucovorin until disease progression. The primary endpoint is overall response rate according to RECIST 1.1 criteria., Discussion: The relative benefit of chemotherapy intensification when using an anti-EGFR-based regimen in molecularly selected patients is unknown; TRIPLETE study aims at filling this gap of knowledge. The study is sponsored by the Gruppo Oncologico Nord Ovest Cooperative Group and is currently ongoing at 42 Italian centres., Clinical Trial Information: NCT03231722., Competing Interests: Competing interests: None declared.- Published
- 2018
- Full Text
- View/download PDF
148. Bevacizumab maintenance in metastatic colorectal cancer: How long?
- Author
-
De Stefano A, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Di Pietro F, Pepe S, De Placido S, and Carlomagno C
- Abstract
The management of patients with non-progressive metastatic colorectal cancer after six months of treatment has not yet been codified. The most relevant concerns are the effectiveness of maintenance vs discontinuation, and the tolerability of prolonged treatment. Here we report the case of a 72-year-old man affected by colorectal cancer with lung metastases who achieved a complete response after receiving capecitabine, oxaliplatin and bevacizumab for six months, and bevacizumab alone for six months. Bevacizumab was continued as maintenance regimen for more than three years. It was discontinued because of an arthroplasty. Fifty-eight months after beginning first-line treatment, the patient remains free from relapse. Adverse effects were minimal and easily controlled.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.